Wordt geladen...
1ISG-007 Biosimilar of infliximab: does the penetration rate meet expectations? appraisal in a central purchasing office
BACKGROUND: Prescription of biosimilars on a large scale is an important lever to decrease hospital expenses. As a result, 40 M€ of savings are expected in the healthcare bill by the promotion of biosimilar use in 2018. In 2015, one wholesaler (WS) listed one of the two biosimilars of infliximab. PU...
Bewaard in:
| Gepubliceerd in: | Eur J Hosp Pharm |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BMJ Group
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535251/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.7 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|